H1 2026 Trading Update
EKF Diagnostics Holdings plc reported a trading update for the first half of 2026, showing broadly flat revenue at £25.0m compared to £25.2m in the prior year, but an improved gross margin to 53% from 50%. The company maintained a strong cash position of £16.0m with no bank borrowings, despite allocating £0.9m to its share buyback program and continuing growth investments. Key business segments like β-HB revenues grew 4% and Life Sciences saw 20% growth, with Contract Manufacturing performing well. EKF remains on track to meet full-year 2026 revenue and adjusted EBITDA expectations, with consensus forecasts at £54.7m and £13.6m respectively.
Select text to share a quote on X · sign in to keep highlights & notes in your EKF notes
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, provides the following unaudited trading update for the six months ended 30 June 2026 ("H1 2026").
Trading during the period was in line with management expectations, with improved gross margin, growth in adjusted EBITDA and continued cash generation.
Revenue for H1 2026 remained broadly flat at £25.0m (H1 2025: £25.2m), reflecting the higher weighting of sales expected in the second half of the year. Gross margin improved to 53% (H1 2025: 50%) and adjusted EBITDA1 showed continued growth.
The Group's cash balance as at 30 June 2026 was £16.0m (31 December 2025: £15.8m), which included £2.4m held in Russia (31 December 2025: £2.1m). The Company has no bank borrowings, and the closing cash balance reflects the allocation of £1.4m for the ongoing share buyback programme, of which £0.9m has been deployed during the period, together with the continued investment for growth that is part of the five-year strategic development plan for the business.
The progress of the five-year strategy continues in line with management expectations. Diabetes and Hematology delivered steady performances in the first half, with the majority of high-volume tenders already won and scheduled to be delivered in the historically stronger H2. β-HB revenues grew by 4%, exceeding first half expectations, and overall Life Sciences continues to deliver high growth 20%, with Contract Manufacturing performing particularly well in the first half.
The Company remains on track to deliver growth at the revenue and adjusted EBITDA levels for FY 2026 in line with current market expectations2.
EKF will announce unaudited results for H1 2026 on 15 September 2026.
1 Earnings before interest, tax, depreciation and amortisation, excluding exceptional items.
² Management understands consensus revenue and Adjusted EBITDA forecasts for FY 2026 to be £54.7m and £13.6m respectively.
The person responsible for arranging the release of this Announcement
on behalf of the Company is Gavin Jones, Chief Executive Officer.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com |
| Julian Baines, Executive Chair | via Walbrook PR |
| Gavin Jones, Chief Executive Officer | |
| Helen Jones, Chief Financial Officer | |
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 |
| Jen Boorer / Russell Cook / Patrick Weaver | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.